Scholarlink

Background <p>Aim of this study was to analyze the safety of prostate-specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) with preexisting mild to moderate leukopenia (CTCAE ≥ 1).</p> Results <p>Thirty-seven mCRPC patients with preexisting leukopenia (leukocyte count &lt; 3.8 × 10<sup>9</sup>/L) were included in this study. Patients received a median of 3 cycles of [<sup>177</sup>Lu]Lu-PSMA-617 (range 1–9). No significant difference in leukocyte counts was observed between baseline and follow-up after each PSMA-RLT cycle: first cycle (3.0 ± 0.5 at baseline vs. 3.4 ± 1.4 at follow up [in × 10<sup>9</sup>/L], <i>p</i> = 0.0921), second cycle (3.1 ± 0.4 vs. 3.8 ± 1.7, <i>p</i> = 0. 0.0509), and third cycle (3.1 ± 0.4 vs. 3.2 ± 2.0, <i>p</i> = 0.2929), respectively. Similarly, baseline and end of treatment values, irrespective of the number of administered cycles, did not reveal a significant difference (3.0 ± 0.5 vs. 3.5 ± 1.4, <i>p</i> = 0.0684). After the end of therapy, irrespective of the number of administered cycles, 27% patients remained stable in terms of CTCAE scoring, 46% changed to a higher score and 27% improved to a lower score.</p> Conclusion <p>Although marked preexisting leukopenia is often considered a relative contraindication for PSMA-RLT, our findings indicate that PSMA-RLT is feasible in patients with leukopenia of CTCAE grade ≥ 1. In our cohort, leukocyte counts remained stable without significant RLT-induced deterioration. Therefore, patients with leukopenia should not be categorically excluded from receiving PSMA-RLT.</p> <p><i>Trial registration</i>: Clinicaltrials.gov identifier: NCT04833517, registered 01.01.2016.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月6日

查看全文
  • Moritz B. Bastian,
  • Tilman Speicher,
  • Arne Blickle,
  • Caroline Burgard,
  • Julius L. D. Bastian,
  • Mark Bartholomä,
  • Andrea Schaefer-Schuler,
  • Stephan Maus,
  • Samer Ezziddin,
  • Florian Rosar

摘要

Background

Aim of this study was to analyze the safety of prostate-specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) with preexisting mild to moderate leukopenia (CTCAE ≥ 1).

Results

Thirty-seven mCRPC patients with preexisting leukopenia (leukocyte count < 3.8 × 109/L) were included in this study. Patients received a median of 3 cycles of [177Lu]Lu-PSMA-617 (range 1–9). No significant difference in leukocyte counts was observed between baseline and follow-up after each PSMA-RLT cycle: first cycle (3.0 ± 0.5 at baseline vs. 3.4 ± 1.4 at follow up [in × 109/L], p = 0.0921), second cycle (3.1 ± 0.4 vs. 3.8 ± 1.7, p = 0. 0.0509), and third cycle (3.1 ± 0.4 vs. 3.2 ± 2.0, p = 0.2929), respectively. Similarly, baseline and end of treatment values, irrespective of the number of administered cycles, did not reveal a significant difference (3.0 ± 0.5 vs. 3.5 ± 1.4, p = 0.0684). After the end of therapy, irrespective of the number of administered cycles, 27% patients remained stable in terms of CTCAE scoring, 46% changed to a higher score and 27% improved to a lower score.

Conclusion

Although marked preexisting leukopenia is often considered a relative contraindication for PSMA-RLT, our findings indicate that PSMA-RLT is feasible in patients with leukopenia of CTCAE grade ≥ 1. In our cohort, leukocyte counts remained stable without significant RLT-induced deterioration. Therefore, patients with leukopenia should not be categorically excluded from receiving PSMA-RLT.

Trial registration: Clinicaltrials.gov identifier: NCT04833517, registered 01.01.2016.